M. Haughey

BRAF and NRAS mutations in circulating Langerhans-like CD1a+ cells in a patient with pulmonary Langerhans’ cell histiocytosis

T. Colby, J. Moss, J. Kato, 2017, European Respiratory Journal.

Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.

J. Moss, M. Stylianou, Suowen Xu, 2014, Chest.

Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.

J. Moss, Ji-an Wang, E. Cowen, 2015, Journal of the American Academy of Dermatology.

CA‐125 in Disease Progression and Treatment of Lymphangioleiomyomatosis

J. Moss, M. Stylianou, Connie G. Glasgow, 2017, Chest.

Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.

J. Moss, Jing-Ping Lin, S. El-Chemaly, 2010, American journal of respiratory and critical care medicine.

Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

J. Moss, J. Kato, V. Manganiello, 2015, American journal of respiratory and critical care medicine.

Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial

D. Bienfang, E. Henske, J. Moss, 2017, Chest.

Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation.

W. Gahl, N. Young, J. Moss, 2011, Chest.

BRAF and NRAS mutations in circulating Langerhans-like CD1a+ cells in a patient with pulmonary Langerhans’ cell histiocytosis

T. Colby, J. Moss, J. Kato, 2017, European Respiratory Journal.